Lumos Diagnostics Holdings Limited (ASX:LDX)

Australia · Delayed Price · Currency is AUD

0.1000

0.00 (0.00%)

Aug 28, 2026, 4:10 PM AEST

-23.08% (1Y)

Market Cap	94.44M +19.4%
Revenue (ttm)	19.07M +6.4%
Net Income	-7.16M
EPS	-0.01
Shares Out	944.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,608,144
Open	0.1050
Previous Close	0.1000
Day's Range	0.0980 - 0.1050
52-Week Range	0.0760 - 0.3300
Beta	0.54
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 20, 2026

About ASX:LDX

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platfor... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2018

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol LDX

Full Company Profile

Financial Performance

In fiscal year 2026, ASX:LDX's revenue was $13.19 million, an increase of 6.39% compared to the previous year's $12.40 million. Losses were -$4.95 million, -31.06% less than in 2025.

Financial numbers in USD Financial Statements